Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: Metabolic reprogramming based on RNA sequencing of gemcitabine-resistant cells reveals the FASN gene as a therapeutic for bladder cancer

Fig. 2

Establishment of an RM-RM to Predict the OS of BLCA Patients. A, B Least absolute shrinkage and selection operator (LASSO) Cox regression of OS-related key drug resistance and metabolism-related differentially expressed genes (RM-DEGs). C Multivariate Cox regression analysis was performed on seven key genes obtained based on cross validation and the minimum partial likelihood deviance. D The drug resistance and metabolism-related risk score (RM-RS) distribution of the cancer genome atlas (TCGA) BLCA. The median was the dividing line, blue was the low RM-RS subgroup, and red was the high RM-RS subgroup. E The overall survival distribution of the two subgroups. Blue represents alive, while red represent death. F Kaplan‒Meier analysis of overall survival (OS) curves of TCGA BLCA patients in the two subgroups. G The receiver operating characteristic (ROC) curves of 1-, 3-, and 5 year OS of patients in TCGA BLCA database was predicted based on RM-RS. H Comparison of ROC curves between RM-RS and clinical features. I Univariate and multivariate Cox regression analyses of RM-RS and clinical features. J The heatmap of RM-RM 7 component gene expression in the TCGA BLCA database, including RM-RS and clinical features

Back to article page